The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
MeSH Review

Blast Crisis

Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of Blast Crisis


High impact information on Blast Crisis


Chemical compound and disease context of Blast Crisis


Biological context of Blast Crisis

  • Eight examples of mutations in the open reading frame of the p53 gene at codons 49, 53, 60, 140, 202, 204, 238, and 239 were observed in blast crisis patients [2].
  • Taken together, these data indicate that a MPD can arise in mice without expression of BCR/ABL in HSCs and that additional mutations inhibiting programmed cell death may be critical in the transition of this disease to blast-crisis leukemia [15].
  • In addition, a presently unidentified transforming gene (neither RAS nor RAF) was detected in 1 patient with chronic phase and 1 with blast crisis [16].
  • Progression of CML to acute leukemia (blast crisis) in humans has been associated with acquisition of secondary chromosomal translocations, including the t(7;11)(p15;p15) resulting in the NUP98/HOXA9 fusion protein [17].
  • These observations suggest that abnormalities of the p53 anti-oncogene are temporally related to the clinical progression of some cases of CML and are probably responsible for the development of blast crisis in these cases [18].

Anatomical context of Blast Crisis


Gene context of Blast Crisis


Analytical, diagnostic and therapeutic context of Blast Crisis

  • Northern blot analysis showed that the GST-Pi gene was expressed in the leukemic cells at blast crisis but not at chronic phase; however, no fusion mRNA between GST-Pi and bcr was identified [27].
  • RESULTS: Imatinib showed clinically and statistically significantly better results for time-to-progression to accelerated phase or blast crisis, progression-free survival, complete hematological response rate, and cytogenetic response rate [28].
  • The expression of hSecurin was assessed by real-time quantitative PCR in samples from patients with acute myeloid leukaemia (AML, n=70), chronic myeloid leukaemia (CML) in chronic phase (CP, n=20) or blast phase (BP, n=12), and granulocytes as well as mononuclear cells (MNCs) from healthy donors (n=21) [29].
  • Different suppression of Ph1 positive hemopoiesis induced by intensive chemotherapy in lymphoid and myeloid blast crisis of CML [30].
  • Between June 1979 and October 1983, 14 autografts were performed in 13 patients with CML (ten blast crisis, four accelerated phase) [31].


  1. Preliminary observations on the therapy of the myeloid blast phase of chronic granulocytic leukemia with plicamycin and hydroxyurea. Koller, C.A., Miller, D.M. N. Engl. J. Med. (1986) [Pubmed]
  2. The spectrum of molecular alterations in the evolution of chronic myelocytic leukemia. Ahuja, H., Bar-Eli, M., Arlin, Z., Advani, S., Allen, S.L., Goldman, J., Snyder, D., Foti, A., Cline, M. J. Clin. Invest. (1991) [Pubmed]
  3. Glucocorticosteroids induce DNA fragmentation in human lymphoid leukemia cells. Distelhorst, C.W. Blood (1988) [Pubmed]
  4. Adenosine deaminase and ecto-5'-nucleotidase activities in various leukemias with special reference to blast crisis: significance of ecto-5'-nucleotidase in lymphoid blast crisis of chronic myeloid leukemia. Koya, M., Kanoh, T., Sawada, H., Uchino, H., Ueda, K. Blood (1981) [Pubmed]
  5. Kit ligand/mast cell growth factor-independent differentiation of mast cells in myelodysplasia and chronic myeloid leukemic blast crisis. Valent, P., Spanblöchl, E., Bankl, H.C., Sperr, W.R., Marosi, C., Pirc-Danoewinata, H., Virgolini, I., Eichler, H.G., Agis, H., Sillaber, C. Blood (1994) [Pubmed]
  6. Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. Druker, B.J., Sawyers, C.L., Kantarjian, H., Resta, D.J., Reese, S.F., Ford, J.M., Capdeville, R., Talpaz, M. N. Engl. J. Med. (2001) [Pubmed]
  7. Proliferating cell nuclear antigen in blast crisis cells of patients with chronic myeloid leukemia. Takasaki, Y., Robinson, W.A., Tan, E.M. J. Natl. Cancer Inst. (1984) [Pubmed]
  8. A phase I-II trial of multiple-dose polyriboinosic-polyribocytidylic acid in patieonts with leukemia or solid tumors. Robinson, R.A., DeVita, V.T., Levy, H.B., Baron, S., Hubbard, S.P., Levine, A.S. J. Natl. Cancer Inst. (1976) [Pubmed]
  9. Target cell in chronic myeloid leukaemia and its relationship to acute lymphoid leukaemia. Janossy, G., Roberts, M., Greaves, M.F. Lancet (1976) [Pubmed]
  10. Clinical resistance to the kinase inhibitor STI-571 in chronic myeloid leukemia by mutation of Tyr-253 in the Abl kinase domain P-loop. Roumiantsev, S., Shah, N.P., Gorre, M.E., Nicoll, J., Brasher, B.B., Sawyers, C.L., Van Etten, R.A. Proc. Natl. Acad. Sci. U.S.A. (2002) [Pubmed]
  11. Incidence of involvement of the B and T lymphocyte lineages in chronic myelogenous leukemia. Nitta, M., Kato, Y., Strife, A., Wachter, M., Fried, J., Perez, A., Jhanwar, S., Duigou-Osterndorf, R., Chaganti, R.S., Clarkson, B. Blood (1985) [Pubmed]
  12. Biochemically directed therapy of leukemia with tiazofurin, a selective blocker of inosine 5'-phosphate dehydrogenase activity. Tricot, G.J., Jayaram, H.N., Lapis, E., Natsumeda, Y., Nichols, C.R., Kneebone, P., Heerema, N., Weber, G., Hoffman, R. Cancer Res. (1989) [Pubmed]
  13. High-dose cytosine arabinoside: treatment and cellular pharmacology of chronic myelogenous leukemia blast crisis. Iacoboni, S.J., Plunkett, W., Kantarjian, H.M., Estey, E., Keating, M.J., McCredie, K.B., Freireich, E.J. J. Clin. Oncol. (1986) [Pubmed]
  14. In vitro studies on the mechanism of action of hepsulfam in chronic myelogenous leukemia patients. Hincks, J.R., Adlakha, A., Cook, C.A., Johnson, C.S., Furmanski, P., Gibson, N.W. Cancer Res. (1990) [Pubmed]
  15. Expression of BCR/ABL and BCL-2 in myeloid progenitors leads to myeloid leukemias. Jaiswal, S., Traver, D., Miyamoto, T., Akashi, K., Lagasse, E., Weissman, I.L. Proc. Natl. Acad. Sci. U.S.A. (2003) [Pubmed]
  16. Transforming genes in chronic myelogenous leukemia. Liu, E., Hjelle, B., Bishop, J.M. Proc. Natl. Acad. Sci. U.S.A. (1988) [Pubmed]
  17. A murine model of CML blast crisis induced by cooperation between BCR/ABL and NUP98/HOXA9. Dash, A.B., Williams, I.R., Kutok, J.L., Tomasson, M.H., Anastasiadou, E., Lindahl, K., Li, S., Van Etten, R.A., Borrow, J., Housman, D., Druker, B., Gilliland, D.G. Proc. Natl. Acad. Sci. U.S.A. (2002) [Pubmed]
  18. Correlation between molecular and clinical events in the evolution of chronic myelocytic leukemia to blast crisis. Foti, A., Ahuja, H.G., Allen, S.L., Koduru, P., Schuster, M.W., Schulman, P., Bar-Eli, M., Cline, M.J. Blood (1991) [Pubmed]
  19. Protein tyrosine phosphatase PTP1B suppresses p210 bcr-abl-induced transformation of rat-1 fibroblasts and promotes differentiation of K562 cells. LaMontagne, K.R., Hannon, G., Tonks, N.K. Proc. Natl. Acad. Sci. U.S.A. (1998) [Pubmed]
  20. Absence of alternative splicing in bcr-abl mRNA in chronic myeloid leukemia cell lines. Hermans, A., Selleri, L., Gow, J., Grosveld, G.C. Blood (1988) [Pubmed]
  21. Recognition of BCR-ABL positive leukemic blasts by human CD4+ T cells elicited by primary in vitro immunization with a BCR-ABL breakpoint peptide. Bosch, G.J., Joosten, A.M., Kessler, J.H., Melief, C.J., Leeksma, O.C. Blood (1996) [Pubmed]
  22. Propagation of human blastic myeloid leukemias in the SCID mouse. Sawyers, C.L., Gishizky, M.L., Quan, S., Golde, D.W., Witte, O.N. Blood (1992) [Pubmed]
  23. Expression of the hematopoietic growth factor receptor FLT3 (STK-1/Flk2) in human leukemias. Carow, C.E., Levenstein, M., Kaufmann, S.H., Chen, J., Amin, S., Rockwell, P., Witte, L., Borowitz, M.J., Civin, C.I., Small, D. Blood (1996) [Pubmed]
  24. Constitutive expression of SOCS3 confers resistance to IFN-alpha in chronic myelogenous leukemia cells. Sakai, I., Takeuchi, K., Yamauchi, H., Narumi, H., Fujita, S. Blood (2002) [Pubmed]
  25. Down-regulation of BRCA1 in BCR-ABL-expressing hematopoietic cells. Deutsch, E., Jarrousse, S., Buet, D., Dugray, A., Bonnet, M.L., Vozenin-Brotons, M.C., Guilhot, F., Turhan, A.G., Feunteun, J., Bourhis, J. Blood (2003) [Pubmed]
  26. The preferential expression of CD7 and CD34 in myeloid blast crisis in chronic myeloid leukemia. Kosugi, N., Tojo, A., Shinzaki, H., Nagamura-Inoue, T., Asano, S. Blood (2000) [Pubmed]
  27. Molecular characterization of a variant Ph1 translocation t(9;22;11) (q34;q11;q13) in chronic myelogenous leukemia (CML) reveals the translocation of the 3'-part of BCR gene to the chromosome band 11q13. Koduru, P.R., Goh, J.C., Pergolizzi, R.G., Lichtman, S.M., Broome, J.D. Oncogene (1993) [Pubmed]
  28. Approval summary: imatinib mesylate capsules for treatment of adult patients with newly diagnosed philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase. Johnson, J.R., Bross, P., Cohen, M., Rothmann, M., Chen, G., Zajicek, A., Gobburu, J., Rahman, A., Staten, A., Pazdur, R. Clin. Cancer Res. (2003) [Pubmed]
  29. High expression of the sister-chromatid separation regulator and proto-oncogene hSecurin occurs in a subset of myeloid leukaemias but is not implicated in the pathogenesis of aneuploidy. Auner, H.W., Zebisch, A., Schimek, M.G., Bodner, C., Hiden, K., Linkesch, W., Haas, O.A., Beham-Schmid, C., Sill, H. Leukemia (2004) [Pubmed]
  30. Different suppression of Ph1 positive hemopoiesis induced by intensive chemotherapy in lymphoid and myeloid blast crisis of CML. Guerrasio, A., Martinelli, G., Ambrosetti, A., Falda, M., Paolino, F., Rege-Cambrin, G., Rosso, C., Pignatti, P.F., Gasparini, P., Perona, G. Haematologica (1991) [Pubmed]
  31. Autologous marrow transplantation for patients with chronic myeloid leukemia in accelerated or blastic phase: report of 14 cases. Lemonnier, M.P., Gorin, N.C., Laporte, J.P., Douay, L., Lopez, M., van den Akker, J., Stachowiak, J., David, R., Pene, F., Kantor, G. Exp. Hematol. (1986) [Pubmed]
WikiGenes - Universities